The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Shares of Cartesian Therapeutics rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year. Shares were up 29% to $8.81 in Monday afternoon ...
Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...
One important aspect of behavioural studies is quantifying how animals move. Recently developed tools such as DeepLabCut and SLEAP, have made it easier for researchers to track how animals move. These ...
NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation III (the “Company”) announced today the closing of its initial public offering of 27,600,000 units, including 3,600,000 units pursuant to the ...
Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25 Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol Assessment ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company's share price sank ...
Cartesian Therapeutics has claimed a phase 2b win for its BCMA-directed CAR-T therapy in generalized myasthenia gravis (gMG). But the biotech’s victory came on a primary endpoint it changed in May and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results